$CDXS
CODEXIS, INC. Stock $cdxs

$cdxs Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000120037524000009 Filed on February 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$17.07M	$26.56M	$70.14M
YoY Change	31.51%	-12.56%	-49.39%
Cost Of Revenue	$4.855M	$2.862M	$12.81M
YoY Change	7.39%	-66.15%	-66.32%
Gross Profit	$12.22M	$23.70M	$57.33M
YoY Change	44.4%	8.12%	-42.98%
Gross Profit Margin	71.56%	89.22%	81.74%
Selling, General & Admin	$12.86M	$12.18M	$53.25M
YoY Change	-16.49%	-1.06%	2.07%
% of Gross Profit	105.25%	51.41%	92.88%
Research & Development	$11.25M	$11.23M	$58.89M
YoY Change	-32.48%	-42.94%	-26.48%
% of Gross Profit	92.04%	47.4%	102.71%
Depreciation & Amortization	$1.252M	$1.216M	$5.518M
YoY Change	-14.6%	-16.66%	2.15%
% of Gross Profit	10.25%	5.13%	9.62%
Operating Expenses	$24.11M	$23.42M	$112.1M
YoY Change	-24.8%	-26.83%	-15.22%
Operating Profit	-$11.89M	$281.0K	-$68.07M
YoY Change	-49.77%	-102.79%	95.15%
Interest Expense	$909.0K	$906.0K	$4.172M
YoY Change	-16.53%	10.09%	189.52%
% of Operating Profit		322.42%
Other Income/Expense, Net	-$516.0K	-$8.344M	-$12.27M
YoY Change	1964.0%	31992.31%	-9998.39%
Pretax Income	-$11.50M	-$7.157M	-$76.17M
YoY Change	-49.14%	-42.53%	128.63%
Income Tax	$10.00K	$35.00K	$69.00K
% Of Pretax Income
Net Earnings	-$11.51M	-$7.192M	-$76.24M
YoY Change	-49.13%	-42.94%	126.96%
Net Earnings / Revenue	-67.39%	-27.08%	-108.69%
Basic Earnings Per Share	-$0.16		-$1.12
Diluted Earnings Per Share	-$0.16	-$0.10	-$1.12
COMMON SHARES
Basic Shares Outstanding	70.30M shares	69.83M shares	68.13M shares
Diluted Shares Outstanding	69.85M shares		68.13M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$85.52M	$65.12M	$65.12M
YoY Change	-16.84%	-42.87%	-42.87%
Cash & Equivalents	$58.05M	$65.10M	$65.12M
Short-Term Investments	$27.47M
Other Short-Term Assets	$500.0K	$600.0K	$5.737M
YoY Change	-90.22%	-90.01%	-4.51%
Inventory	$2.441M	$2.685M	$2.685M
Prepaid Expenses	$4.700M	$4.600M
Receivables	$14.21M	$10.04M	$19.93M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$107.9M	$93.47M	$93.47M
YoY Change	-16.93%	-42.62%	-42.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.67M	$15.49M	$28.62M
YoY Change	-37.87%	-31.52%	-53.74%
Goodwill	$2.463M	$2.463M
YoY Change	-23.03%	-23.03%
Intangibles
YoY Change
Long-Term Investments	$9.700M	$9.700M	$9.700M
YoY Change	-54.48%	-52.71%	-52.71%
Other Assets	$1.354M	$1.246M	$2.308M
YoY Change	226.27%	256.0%	23.36%
Total Long-Term Assets	$41.61M	$43.10M	$43.10M
YoY Change	-52.78%	-50.75%	-50.75%
TOTAL ASSETS
Total Short-Term Assets	$107.9M	$93.47M	$93.47M
Total Long-Term Assets	$41.61M	$43.10M	$43.10M
Total Assets	$149.6M	$136.6M	$136.6M
YoY Change	-31.42%	-45.46%	-45.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.465M	$5.947M	$5.947M
YoY Change	-22.9%	83.21%	83.21%
Accrued Expenses	$5.374M	$4.735M	$19.76M
YoY Change	-35.56%	-69.01%	-38.42%
Deferred Revenue	$9.860M	$3.781M
YoY Change	-26.27%	-72.46%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$29.08M	$35.83M	$35.83M
YoY Change	-24.09%	-26.98%	-26.98%
LONG-TERM LIABILITIES
Long-Term Debt	$28.10M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.248M	$1.233M	$14.12M
YoY Change	-10.09%	-10.07%	-75.03%
Total Long-Term Liabilities	$29.35M	$1.233M	$14.12M
YoY Change	2014.55%	-10.07%	-75.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.08M	$35.83M	$35.83M
Total Long-Term Liabilities	$29.35M	$1.233M	$14.12M
Total Liabilities	$70.29M	$49.95M	$49.95M
YoY Change	-23.64%	-52.7%	-52.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$509.0M	-$497.5M
YoY Change	14.67%	18.1%
Common Stock	$7.000K	$7.000K
YoY Change	16.67%	16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$79.27M	$86.62M	$86.62M
YoY Change
Total Liabilities & Shareholders Equity	$149.6M	$136.6M	$136.6M
YoY Change	-31.42%	-45.46%	-45.46%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$11.51M	-$7.192M	-$76.24M
YoY Change	-49.13%	-42.94%	126.96%
Depreciation, Depletion And Amortization	$1.252M	$1.216M	$5.518M
YoY Change	-14.6%	-16.66%	2.15%
Cash From Operating Activities	-$7.789M	-$11.04M	-$52.64M
YoY Change	-15.45%	-324.47%	-566.48%
INVESTING ACTIVITIES
Capital Expenditures	$1.130M	-$380.0K	$4.418M
YoY Change	-55.49%	1051.52%	-46.82%
Acquisitions
YoY Change
Other Investing Activities	-$27.43M	$724.0K	-$440.0K
YoY Change	3582.28%		-91.65%
Cash From Investing Activities	-$28.56M	$1.104M	-$4.858M
YoY Change	769.76%	3245.45%	-64.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$8.652M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$29.28M	-3.000K	$8.167M
YoY Change	2065.75%	-100.88%	-1520.35%
NET CHANGE
Cash From Operating Activities	-$7.789M	-11.04M	-$52.64M
Cash From Investing Activities	-$28.56M	1.104M	-$4.858M
Cash From Financing Activities	$29.28M	-3.000K	$8.167M
Net Change In Cash	-$7.071M	-9.933M	-$49.33M
YoY Change	-36.55%	-287.8%	1619.38%
FREE CASH FLOW
Cash From Operating Activities	-$7.789M	-$11.04M	-$52.64M
Capital Expenditures	$1.130M	-$380.0K	$4.418M
Free Cash Flow	-$8.919M	-$10.66M	-$57.06M
YoY Change	-24.1%	-315.29%	-2016.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58885000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	53250000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	52172000	usd
CY2023	us-gaap	Restructuring Charges RestructuringCharges	3284000	usd
CY2022	us-gaap	Restructuring Charges RestructuringCharges	3167000	usd
CY2021	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	36000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116026000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118895000	usd
CY2023	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	0	usd
CY2022	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2038000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12809000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	38033000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	80099000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55919000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	49323000	usd
CY2021	cdxs	Asset Impairment And Other Charges AssetImpairmentAndOtherCharges	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	955000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5180000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8652000	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	503000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001200375
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-34705
CY2023	dei	Entity Registrant Name EntityRegistrantName	Codexis, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	71-0872999
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	200 Penobscot Drive
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94063
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	421-8100
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	CDXS
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	122400000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70303639	shares
CY2023	dei	Auditor Name AuditorName	BDO USA, P.C.
CY2023	dei	Auditor Location AuditorLocation	San Francisco, CA
CY2023	dei	Auditor Firm AuditorFirmId	243
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65116000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113984000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	519000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	521000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10036000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	31904000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	815000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	2116000	usd
CY2023Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	9142000	usd
CY2022Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	7016000	usd
CY2023Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	19993000	usd
CY2022Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	41036000	usd
CY2023Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	65000	usd
CY2022Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	163000	usd
CY2023Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	19928000	usd
CY2022Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	40873000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2685000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2029000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5218000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5487000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	93466000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	162894000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1062000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1521000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	9700000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	20510000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13137000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39263000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15487000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22614000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	2463000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3241000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1246000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	350000	usd
CY2023Q4	us-gaap	Assets Assets	136561000	usd
CY2022Q4	us-gaap	Assets Assets	250393000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5947000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3246000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11246000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11453000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4735000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15279000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3781000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5360000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10121000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13728000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	35830000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	49066000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	640000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16881000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12243000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	38278000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1233000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1371000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	49946000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	105596000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69905000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69905000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65811000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65811000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	584138000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	566081000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-497530000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-421290000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	86615000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	144797000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	136561000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	250393000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	70143000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	138590000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104754000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	22209000	usd
CY2023	cdxs	Asset Impairment And Other Charges AssetImpairmentAndOtherCharges	9984000	usd
CY2022	cdxs	Asset Impairment And Other Charges AssetImpairmentAndOtherCharges	0	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	173471000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	127451000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-22697000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	124000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1148000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21090000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.12
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68131000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68131000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65344000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	170103000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5180000	usd
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1206000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-21279000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	955000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1488000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33592000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	559000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	721000	usd
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	404000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-76240000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-76240000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33592000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-21279000	usd
CY2023	us-gaap	Depreciation Depreciation	5518000	usd
CY2022	us-gaap	Depreciation Depreciation	5402000	usd
CY2021	us-gaap	Depreciation Depreciation	3113000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4405000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4849000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2834000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	9971000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	14531000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	11593000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-65000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	342000	usd
CY2023	us-gaap	Other Noncash Income OtherNoncashIncome	213000	usd
CY2022	us-gaap	Other Noncash Income OtherNoncashIncome	1245000	usd
CY2021	us-gaap	Other Noncash Income OtherNoncashIncome	1955000	usd
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	208000	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	1272000	usd
CY2023	cdxs	Asset Impairment And Other Charges AssetImpairmentAndOtherCharges	9984000	usd
CY2022	cdxs	Asset Impairment And Other Charges AssetImpairmentAndOtherCharges	0	usd
CY2021	cdxs	Asset Impairment And Other Charges AssetImpairmentAndOtherCharges	0	usd
CY2023	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	12215000	usd
CY2022	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
CY2021	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	4000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-29000	usd
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-19000	usd
CY2023	us-gaap	Increase Decrease In Finance Receivables IncreaseDecreaseInFinanceReceivables	-20247000	usd
CY2022	us-gaap	Increase Decrease In Finance Receivables IncreaseDecreaseInFinanceReceivables	3225000	usd
CY2021	us-gaap	Increase Decrease In Finance Receivables IncreaseDecreaseInFinanceReceivables	9156000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	656000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	869000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	196000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	865000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-181000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2268000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2287000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	207000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	268000	usd
CY2023	cdxs	Increase Decrease In Employee Related Liabilities And Other Accrued Liabilities IncreaseDecreaseInEmployeeRelatedLiabilitiesAndOtherAccruedLiabilities	14041000	usd
CY2022	cdxs	Increase Decrease In Employee Related Liabilities And Other Accrued Liabilities IncreaseDecreaseInEmployeeRelatedLiabilitiesAndOtherAccruedLiabilities	-5983000	usd
CY2021	cdxs	Increase Decrease In Employee Related Liabilities And Other Accrued Liabilities IncreaseDecreaseInEmployeeRelatedLiabilitiesAndOtherAccruedLiabilities	-6575000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-5341000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-5223000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-4147000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-19848000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	24518000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1300000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52638000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	11284000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14267000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4418000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8307000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13828000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	751000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	29000	usd
CY2023	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	1191000	usd
CY2022	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	5300000	usd
CY2021	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	7630000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4858000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13578000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21422000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	422000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	42000	usd
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	207000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	404000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1488000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1206000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8167000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-575000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3767000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-49329000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2869000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-31922000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116026000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118895000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150817000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66697000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	44000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	34000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	14000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	194000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	100000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	102000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1068000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	897000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2533000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65116000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113984000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	116797000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1581000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2042000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2098000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66697000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	Description of Business <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In these notes to the consolidated financial statements, the “Company,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> “we,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> “us,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and “our</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins leveraging our proprietary CodeEvolver</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directed evolution technology platform. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously managed our business as two business segments, Performance Enzymes and Novel Biotherapeutics. During the fourth quarter of 2023, we made changes to the structure of our organization in connection with the restructuring of our business that we announced in July 2023, including the discontinuation of investment in certain development programs, primarily in our biotherapeutics business, consolidation of operations to our Redwood City, California headquarters, and headcount reduction. In connection with these organizational structure changes, corresponding changes were made to how our business is managed, how results are reported internally and how our Chief Executive Officer (“CEO”), our chief operating decision maker, assesses performance and allocates resources. As a result of these changes, our previous Performance Enzymes and Novel Biotherapeutics operating segments were combined into a single reportable segment. Effective October 1, 2023, the Company's operations are managed and reported to the CEO on a consolidated basis. The CEO assesses performance and allocates resources based on the consolidated results of operations. We believe that these changes better align internal resources and external go to market activities in order to create a more efficient and effective organizational structure. Under this new organizational and reporting structure, we managed our business as one reportable segment as of December 31, 2023. Comparative prior period disclosures that reflected the previous two segments' information have been revised to conform to this change in our reportable segment.</span></div>
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, deferred revenue, inventories, valuation of equity investments, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.</span></div>
CY2023	cdxs	Shipping And Distribution Cost ShippingAndDistributionCost	1000000	usd
CY2022	cdxs	Shipping And Distribution Cost ShippingAndDistributionCost	3000000	usd
CY2021	cdxs	Shipping And Distribution Cost ShippingAndDistributionCost	1800000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	300000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	300000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	300000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	500000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	500000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and unbilled receivables, contract assets, non-marketable securities, and restricted cash. Cash that is not required for immediate operating needs is invested principally in money market funds. Cash and cash equivalents are invested through banks and other financial institutions in the United States and India. Such deposits in those countries may be in excess of insured limits. The Company has not experienced material losses on its deposits of cash and cash equivalents.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform ongoing credit evaluations of our customer's financial condition whenever deemed necessary. We maintain an allowance for doubtful accounts based on the expected collectability of all financial assets, which takes into consideration an analysis of historical bad debts, specific customer creditworthiness and current economic trends. As of December 31, 2023, we h</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ad four customers that accounted for 58% of our ac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">counts receivable balance. As of December 31, 2022, two customers accounted for 63% of our accounts receivable balance. We believe the accounts receivable balances from our largest customers do not represent a significant credit risk, based on cash flow forecasts, balance sheet analysis, and past collection experience.</span></div>
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023Q4	us-gaap	Goodwill Goodwill	2500000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3200000	usd
CY2023Q4	cdxs	Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition	48041000	usd
CY2022Q4	cdxs	Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition	136273000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	70143000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	138590000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	70143000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	138590000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104754000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	70143000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	138590000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104754000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	815000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	2116000	usd
CY2023Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	9904000	usd
CY2022Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	7016000	usd
CY2023Q4	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	0	usd
CY2022Q4	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	19000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	10761000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	30609000	usd
CY2021	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	0	usd
CY2023Q4	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	17937000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	4165000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	279000	usd
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1000000	usd
CY2021Q3	us-gaap	Convertible Debt ConvertibleDebt	1300000	usd
CY2021	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	300000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2023	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	12200000	usd
CY2023	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	200000	usd
CY2022	cdxs	Equity Securities Without Readily Determinable Fair Value Realized Upward Downward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueRealizedUpwardDownwardPriceAdjustmentAnnualAmount	0	usd
CY2023	cdxs	Equity Securities Without Readily Determinable Fair Value Realized Upward Downward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueRealizedUpwardDownwardPriceAdjustmentAnnualAmount	0	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	9700000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	20510000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65100000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114000000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	108000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	108000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	7000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	91000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2570000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1830000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2685000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2029000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4600000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	600000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4800000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	700000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	54798000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	62435000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39311000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39821000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15487000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22614000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1500000	usd
CY2023	us-gaap	Depreciation Depreciation	5518000	usd
CY2022	us-gaap	Depreciation Depreciation	5402000	usd
CY2021	us-gaap	Depreciation Depreciation	3113000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3241000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	3241000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	778000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q4	us-gaap	Goodwill Goodwill	2463000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3241000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	2500000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3200000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	2330000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	3495000	usd
CY2023Q4	us-gaap	Purchase Obligation PurchaseObligation	1402000	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	10852000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	1003000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	932000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4735000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15279000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	9971000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	14531000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	11593000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	9971000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	14531000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	11593000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1000000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3385000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.19
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	286000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	26.85
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	664000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.96
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	72000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	17.99
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2935000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.90
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2000000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.90
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	410000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.33
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	275000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	19.01
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4250000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.88
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2046000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.23
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	283000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.97
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	839000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	12.08
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5174000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5174000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5174000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.31
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5174000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.31
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	198000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2231000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.61
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y7M6D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	79000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4748000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.42
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	170000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.31
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.99
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.80
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	700000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3100000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14900000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8200000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-76169000	usd
CY2023Q1	cdxs	Sale Of Stock Securities Registered Aggregate Amount SaleOfStockSecuritiesRegisteredAggregateAmount	200000000	usd
CY2023	cdxs	Sale Of Stock Consideration Received On Transaction Gross SaleOfStockConsiderationReceivedOnTransactionGross	8700000	usd
CY2023	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	7900000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	700000	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1400000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1600000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1100000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-33269000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-21037000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-47000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-53000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-76171000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33316000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21090000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	27000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	141000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	42000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	142000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	198000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	69000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	283000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	198000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-7000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-9000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-9000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	69000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	276000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	189000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15995000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6996000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4429000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2208000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-494000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2235000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	925000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1793000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1132000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	78000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	80000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1967000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	239000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2698000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	438000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-238000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	711000	usd
CY2023	cdxs	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensation	152000	usd
CY2022	cdxs	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensation	80000	usd
CY2021	cdxs	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensation	257000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	16640000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9400000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9635000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	69000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	276000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	189000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	72586000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	69915000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	16412000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	14806000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	176000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1123000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4445000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4967000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2774000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2487000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	457000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	532000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	866000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	424000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	413000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	26821000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	16502000	usd
CY2023Q4	cdxs	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	3608000	usd
CY2022Q4	cdxs	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	9586000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2542000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	125000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	130777000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	120790000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	300000	usd
CY2023Q4	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	77300	sqft
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	127835000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	111183000	usd
CY2023Q4	cdxs	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	2958000	usd
CY2022Q4	cdxs	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	8624000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	736000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	263000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2958000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9623000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	16000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	16000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	16700000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	9400000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	9600000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	18571000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15261000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12683000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2164000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3553000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2206000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	372000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	531000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	243000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	20204000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	18571000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15261000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	42000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	42000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	61000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	600000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	500000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	500000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	300000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	300000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39263000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4405000	usd
CY2023	cdxs	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	898000	usd
CY2023	cdxs	Operating Lease Write Off Due To Lease Modification OperatingLeaseWriteOffDueToLeaseModification	19622000	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	2997000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13137000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	43638000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	9897000	usd
CY2023	cdxs	Operating Lease Interest Accretion OperatingLeaseInterestAccretion	1905000	usd
CY2023	cdxs	Operating Lease Write Off Due To Lease Modification OperatingLeaseWriteOffDueToLeaseModification	19622000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	16024000	usd
CY2023	cdxs	Asset Retirement Obligation Writeoff AssetRetirementObligationWriteoff	200000	usd
CY2023Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	300000	usd
CY2022Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	500000	usd
CY2023	cdxs	Finance Lease Cost FinanceLeaseCost	0	usd
CY2022	cdxs	Finance Lease Cost FinanceLeaseCost	18000	usd
CY2021	cdxs	Finance Lease Cost FinanceLeaseCost	106000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	6310000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	7321000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	4396000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	40000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	70000	usd
CY2023	us-gaap	Lease Cost LeaseCost	6310000	usd
CY2022	us-gaap	Lease Cost LeaseCost	7379000	usd
CY2021	us-gaap	Lease Cost LeaseCost	4572000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	9897000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	6506000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	4197000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	25445000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.066
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4727000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4868000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5014000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2533000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	760000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	318000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	18220000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2196000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	16024000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3781000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12243000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	16024000	usd
CY2023	cdxs	Number Of Business Segments NumberOfBusinessSegments	2	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q3	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	70143000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	138590000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104754000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3241000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	3241000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	778000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q4	us-gaap	Goodwill Goodwill	2463000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3241000	usd
CY2022Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	163000	usd
CY2021Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	416000	usd
CY2020Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	74000	usd
CY2023	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0	usd
CY2022	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	54000	usd
CY2021	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	342000	usd
CY2023	cdxs	Allowance For Credit Loss Write Off AllowanceForCreditLossWriteOff	33000	usd
CY2022	cdxs	Allowance For Credit Loss Write Off AllowanceForCreditLossWriteOff	257000	usd
CY2021	cdxs	Allowance For Credit Loss Write Off AllowanceForCreditLossWriteOff	0	usd
CY2023	cdxs	Allowance For Credit Loss Adjustment AllowanceForCreditLossAdjustment	65000	usd
CY2022	cdxs	Allowance For Credit Loss Adjustment AllowanceForCreditLossAdjustment	50000	usd
CY2021	cdxs	Allowance For Credit Loss Adjustment AllowanceForCreditLossAdjustment	0	usd
CY2023Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	65000	usd
CY2022Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	163000	usd
CY2021Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	416000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	10036000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	31904000	usd
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
cdxs-20231231_cal.xml	Edgar Link	unprocessable
0001200375-24-000009-index-headers.html	Edgar Link	pending
0001200375-24-000009-index.html	Edgar Link	pending
0001200375-24-000009.txt	Edgar Link	pending
0001200375-24-000009-xbrl.zip	Edgar Link	pending
cdxs-20231231.htm	Edgar Link	pending
cdxs-20231231.xsd	Edgar Link	pending
cdxs-20231231_g1.jpg	Edgar Link	pending
codexis-ex1011codexis_nest.htm	Edgar Link	pending
codexis-ex1017codexis_inno.htm	Edgar Link	pending
codexis-ex971policyonrecou.htm	Edgar Link	pending
exhibit231auditconsent2023.htm	Edgar Link	pending
exhibit311cdxs-20231231.htm	Edgar Link	pending
exhibit312cdxs-20231231.htm	Edgar Link	pending
exhibit321cdxs-20231231.htm	Edgar Link	pending
exhibit44cdxs-20231231.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
cdxs-20231231_def.xml	Edgar Link	unprocessable
cdxs-20231231_lab.xml	Edgar Link	unprocessable
cdxs-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cdxs-20231231_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDXS
CODEXIS, INC. Stock $cdxs

2024 Q1 Form 10-K Financial Statement

#000120037524000009 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXS CODEXIS, INC. Stock $cdxs

2024 Q1 Form 10-K Financial Statement

#000120037524000009 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXS
CODEXIS, INC. Stock $cdxs